TLDR
- Stryker (SYK) dropped 8.9% to a new 52-week low of $275.10 on Wednesday
- Wells Fargo cut its price target from $418 to $348 while keeping an Overweight rating
- The firm lowered its 2026 revenue estimate to $27,209M, below Stryker’s own guidance range
- Analysts still hold a “Moderate Buy” consensus with an average target of $386.28
- Insiders sold over 351,000 shares worth roughly $118.2 million in the last quarter
Stryker (SYK) fell 8.9% to $276.16 on Wednesday, touching a new 52-week low of $275.10 during the session. The stock is now trading well below its 50-day moving average of $327.52 and its 200-day moving average of $328.30.
The selloff came after Wells Fargo trimmed its price target on SYK to $348 from $418, though the firm held its Overweight rating. The cut followed Stryker’s appearance at the 2026 Wells Fargo Healthcare Conference in Boston, where CFO Preston Wells and VP of Investor Relations Nick Mead represented the company.
Wells Fargo lowered its 2026 revenue estimate to $27,209 million from $27,325 million. That implies organic growth of 8.1%, which sits below Stryker’s own guidance range of 8.3% to 9.3%.
The firm also cut its Q3 organic growth estimate to 8.9% from 10.1%. Wells Fargo cited continued pressure on peripheral vascular products and hip and knee segments globally for the remainder of the year.
Adjusted EPS for 2026 was revised down to $14.95 from $15.02, landing at the low end of Stryker’s guidance range of $14.95 to $15.10.
Analyst Views Still Mostly Positive
Despite the pressure, Wall Street hasn’t turned its back on Stryker. The stock carries a “Moderate Buy” consensus rating, with one Strong Buy, seventeen Buy ratings, and six Hold ratings among analysts.
The average price target sits at $386.28, still well above current levels. Piper Sandler kept its Overweight rating but cut its target to $390. JPMorgan lowered its target to $350, also maintaining Overweight. Leerink Partners holds an Outperform with a $407 target.
Stryker last reported Q2 2026 earnings on July 30th. Adjusted EPS came in at $3.69, beating the $3.49 consensus by $0.20. Revenue was $6.59 billion, just ahead of the $6.58 billion estimate.
Quarterly revenue was up 9.4% year over year. EPS grew 18% compared to the same period last year.
Following the results, Wolfe Research raised its target to $375 from $350 while keeping an Outperform rating. Citizens moved in the other direction, cutting its target to $400 from $440, pointing to supply chain issues and a cyberattack earlier in the fiscal year.
Insider Selling Raises Eyebrows
Insider activity has been a talking point. In the last quarter, insiders sold 351,267 shares worth approximately $118.2 million.
Insider Debra King sold 826 shares on August 18th at $336.30 per share. Dylan Crotty sold 441 shares on August 21st at $328.61 per share. Corporate insiders currently hold 4.60% of the stock.
On the institutional side, California State Teachers Retirement System made a large addition in Q2. The fund now holds 163.4 million shares valued at roughly $51.4 billion.
Stryker declared a quarterly dividend of $0.88 per share, payable October 30th to investors of record as of September 30th. The annualized dividend comes to $3.52, with a yield of around 1.3%.
The company has set full-year 2026 EPS guidance at $14.95 to $15.10. Analysts on average expect $15.03 for the fiscal year.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
